![Marcella Ruddy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marcella Ruddy
Directeur/Membre du Conseil chez POLAREAN IMAGING PLC
Fortune : 571 761 $ au 31/05/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Christian Cortis | M | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | - |
Alise Reicin | M | 63 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | 4 ans |
Kenneth West | M | - | - | |
Bastiaan Driehuys | M | - | - | |
Timothy Springer | M | 76 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | - |
Charles Osborne | M | 58 | 5 ans | |
Bill Blair | M | 69 | 1 ans | |
Eran Perry | M | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 ans |
Andrew Kruse | M | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | - |
Christopher von Jako | M | 53 | 1 ans | |
Edd Fleming | M | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 ans |
Terry Mcguire | - | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | - |
Alex Dusek | M | - | 5 ans | |
Alex Rosen | M | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 ans |
Cyrille Yann Nicolas Petit | M | 54 | 4 ans | |
Stefan Vitorovic | M | 39 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | - |
Ronald Renaud | M | 55 |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | - |
Chen-Ming Yu | M | 50 |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 ans |
Jürgen Laucht | M | - | - | |
Stephen Austin | M | 57 | 6 ans | |
Praveen Tipirneni | M | 55 |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | - |
Frank Schulkes | M | 62 | 2 ans | |
Daniel Brague | M | 56 | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Claris Hullihen | M | - | - | |
Bernard Davitian | M | 63 |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 13 | 52,00% |
Royaume-Uni | 12 | 48,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Marcella Ruddy
- Réseau Personnel